

Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 11 th February 2021 8:15am – 9:30am
Venue	Webex
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Mr P O'Brien, Deputy Chief Pharmacist Dr S Raise, GP ER CCG Mr K McCorry, Medicines Optimisation Pharmacist, NECS Dr B Ali, GP Hull CCG Ms J Morgan, Professional Secretary, Principal Pharmacist – Formulary Dr A Samson, Consultant Infectious Diseases Dr O Ogunbambi, Consultant Rheumatologist Prof M Lind, Vice Chair, Professor of Oncology Mr A Dawood, Consultant Anaesthetist
Apologies	Dr H Klonin, Consultant Paediatrician Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics
Guests	Mr R Calladine, Principal Pharmacist EPMA, HUTH Dr S Khan, Consultant Immunologist

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		EPMA Update – Rob Calladine RC gave a brief presentation on the next stages of the EPMA roll out. The surgical corridor at CHH would be the next area to go live with EPMA hopefully this will begin at Easter depending on the pandemic situation. The team have been working on continuous infusions for ITU aswell as working alongside the pain team to improve opioid prescribing in practice. The team are working on adding a new functionality “GP Connect” to the Lorenzo system, which will automatically bring up the patients SCR within system including allergies. This will make it easier to clerk medicines across decreasing the possibility of errors. Once the surgical corridor is up and running the rest of the CHH site will move to EPMA eg cardiology and cardiothoracics then roll out will switch to HRI.	KMc to give John Mitchells details to JM to forward to RC to discuss inclusion of Yorkshire and Humber Care Records		KMc/JM	03/21	
2021.02.01	Apologies	As above					02/21
2021.02.02	Declarations of Interest	None this month					02/21
2021.02.03	Minutes of the previous meeting	Approved					02/21
2021.02.04	Action Tracker	<p>NICE Guidance TA651 Naldemedine for treating opioid induced constipation – JM is still chasing application</p> <p>New Product Request AM to write to applicants</p> <p>New Product Request Upadacitinib – KMc has discussed with ER commissioners who approved but Hull meeting was cancelled so will need to feedback next time</p> <p>New Product Request AM to study evidence on Levosimendan – AM will feedback next time</p>	<p>JM to keep chasing</p> <p>AM has written to applicants</p> <p>KMc to update on Hulls decision next time</p> <p>AM to feedback next time</p>	Action complete	<p>JM</p> <p>AM</p> <p>KMc</p> <p>AM</p>	<p>11/20</p> <p>02/21</p> <p>02/21</p> <p>02/21</p>	02/21

		<p>New Product Request JM has spoken to CHCP regarding adding Liraglutide (Saxenda) to their D&T agenda</p> <p>MHRA DSU AM has sent chapter on Azithromycin/Erythromycin to AD</p> <p>MHRA DSU JM/POB have spoken to critical care pharmacist to request they discuss Erythromycin alert with critical care team</p> <p>CMO Covid 19 Therapeutic Alerts POB has updated Tocilizumab guidance to information on reactivation of Hepatitis B. Guidance has been further updated and will go live tomorrow.</p>	Action complete	No further action	JM	02/21
			Action complete	No further action	AM	02/21
			Action complete	No further action	JM/POB	02/21
			Action complete	No further action	POB	02/21
2021.02.05	New Product Requests	<p>Semaglutide – T2DM – Matthew Heppel Committee assessed all presented evidence, and recognised that endocrinology only wish to use in patients who could not use/tolerate subcutaneous GLP-1 analogues. The committee commented on how complicated the treatment pathway had become and requested it was simplified.</p> <p>Acarizax (Allergen Extract from House Dust Mites) Dr Khan This is the third time the product has been submitted to D&T for discussion. Dr Khan attended D&T in person and gave a presentation demonstrating the reasons why Acarizax was needed. Staloral is no longer available as sublingual option. Acarizax is stronger than the other oral option on formulary Oralvac and contains all 4 dust mite allergens; best practice with Oralvac is to have 2 allergens in 50:50 ratio. Immunology require this treatment as an option for non-responders and are looking at a maximum of 20 patients a year. The committee requested a</p>	Approved AM to write to applicant	<p>AM to write to applicant</p> <p>AM to request a simplified treatment pathway be submitted by the endocrinology team</p>	AM	03/21
			Dr Khan to submit treatment pathway to D&T Committee		SK	03/21

		flow chart to formally demonstrate where Acarizax would sit in the treatment pathway, and agreed after this was presented next time a yes/no decision would be made					
2021.02.06	NICE Guidance	<p>TA668 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer</p> <p>TA669 Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies NOT RECOMMENDED</p> <p>TA670 Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor</p> <p>NG 99 Brain tumours (primary) and brain metastases in adults - Updated link to commissioning statement no change to drugs</p> <p>NG12 Suspected cancer: recognition and referral – updated to include faecal testing no changes to drugs</p>	<p>On formulary</p> <p>On formulary for different indication</p> <p>On formulary</p> <p>Noted</p> <p>Noted</p>	No further action			02/21
2021.02.07	MHRA Drug Safety Update	<p>January 2021</p> <p>Antiepileptic drugs in pregnancy : Updated advice following comprehensive safety review - neurology governance to discuss next week if Epilepsy Society Leaflet which is more patient friendly would be more appropriate for use</p> <p>COVID 19 Vaccines (Pfizer/BioNTech and COVID 19 vaccine AstraZeneca): Current advice – recommends referring to government website for most up to date information</p> <p>Dimethyl Fumarate (Tecfidera) : Updated advice on the progressive multifocal leukoencephalopathy associated with mild lymphopenia</p> <p>Fingolimod (Gilenya) : Updated advice about the risk of serious liver injury and herpes meningoencephalitis</p> <p>Dr Harley aware of updated advice and will change patient monitoring schedules.</p>	<p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p>	No further action			02/21

		SSRI/SNRI Antidepressant medicines:small increased risk of postpartum haemorrhage when used in the month before delivery Aminoglycosides (gentamicin, amikacin, tobramycin and neomycin) : Increased risk of deafness in patients with mitochondrial mutations	Noted Noted				
2021.02.08	Minutes SMPC	November 2020	Noted	No further action			02/21
2021.02.09	Minutes from HERPC	November 2020	Noted	No further action			02/21
2021.02.10	Regional Medicines Optimisation Committees	None this month	No further action				02/21
2021.02.11	Clinical Guidelines	Calcitonin gene-related peptide antagonists for episodic and chronic migraine – updated to include galcanezumab, JM has discussed updates with Spire as they are a primary provider of this service Guidance for Use of Sodium Valproate Updated to include new links to new joint guidance around managing patients from RCGPs and ABN. AM asked what the situation in primary care was and SR said System One asks every time valproate is prescribed if the pregnancy prevention system is in place, SR also said all patients are reviewed by the specialist neurology team once a year and regular audits are completed. Guideline for the prescribing of Gentamicin in Adult Patients Updated to include guidance in pregnancy and surgical prophylaxis. Guidance has already been approved by ACAT Tocilizumab in Patients with Severe COVID-19: A Guideline This has been updated in line with the current CMO letter. HUTH have decided to focus on use of tocilizumab within the two options offered within the CMO letter and therefore not take up Sarilumab as they have similar mode of actions/benefits but	Approved Approved Approved	Add to HERPC agenda	WH	03/21	

		there are lower numbers in Sarilumab arm of Recovery trial and therefore potential for confusion error.					
2021.02.13	Correspondence received	None this month	No further action				02/21
2021.02.14	Chairs approvals	Anakinra – Atypical Stills Disease - Dr Ogunbambi	Noted				02/21
2021.02.15	Issues to escalate to OQC	None this month	No further action				02/21
2021.02.16	Any Other Business	None this month					02/21
	Date and Time of Next Meeting	Date: Thursday 11th March 2021 Time: 8.15-9.30am Venue: Webex					